News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Antares Pharma, Inc. (ANTR) Announces Worldwide Development and License Agreement with Jazz Pharmaceuticals, Inc. (JAZZ); Milestone and Royalty Payments up to $16.5 Million



7/19/2007 11:38:47 AM

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (AMEX: AIS) announced that it has signed a worldwide product development and license agreement with Jazz Pharmaceuticals (NASDAQ: JAZZ). Signing this agreement demonstrates the successful completion of a feasibility agreement which was initiated between Antares and Jazz Pharmaceuticals in December 2005. The product candidate underlying this agreement is being developed to treat a significant CNS disorder and is based on Antares’ proprietary ATD™ (Advanced Transdermal Delivery) system. Approved products from the same class of compounds represented worldwide sales of over $2 billion in 2006, and are projected to achieve sales of at least $3.1 billion in 2010.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES